Dr. Ben Derman, expert in myeloma, discusses key abstracts at ASH23 including new diagnostic criteria for light chain MGUS, trials comparing Dara-VRD vs VRD and Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma, a phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma, long-term follow-up data on salvage transplant in myeloma, overall survival results of KarMMa-3 trial, and a trial comparing Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients. The podcast also covers the revised definition of light chain MGUS, the use of Dara in maintenance therapy, Dara Venetoclaxedex in relapse refractory myeloma, survival results of the Karma 3 trials, and comparing CAR-T therapies.
